ELMWOOD PARK, N.J., May 2, 2019 – BioReference Laboratories, Inc., an OPKO Health Company, along with its women’s health division GenPath, today announced the presentation of new research from its prenatal and hereditary cancer assessment programs at the 2019 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in Nashville, Tennessee from May 3-6. The poster presentations demonstrate the company’s commitment to advancing the research of hereditary conditions.
“Each year ACOG offers the unique opportunity for healthcare providers to learn about extensive research being conducted in most areas affecting a woman’s overall health, this year we are excited to add to that body of research with hereditary condition screening,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories.
A key focus at GenPath’s booth (#1148) this year is our new test offering for vaginal infections and how ObGyns can integrate hereditary condition screening into their practice. The full set of data to be presented includes:
Utilization of Online Family History Collection and Hereditary Cancer Risk Assessment Tool
Author: E. Gabitzsch
E-Poster Session M – 28M
Date: Saturday, May 4
Time: 3:00-4:00 p.m.
Location: Room 209 ABC
Increased Carrier Detection with Expanded Carrier Screening in Multiple Ancestries
Author: X. Yao
E-Poster Session O – 7O
Date: Sunday, May 5
Time: 10:00-11:00 a.m.
Location: Room 209 ABC
About BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups. The company is in network with the five largest health plans in the United States, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 160 MD, PhD and other professional level clinicians and scientists. With a leading position in the areas of genetics, women’s health, maternal-fetal medicine, oncology and urology, BioReference and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine. For more information, visit www.bioreference.com.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company. In diagnostics, its BioReference Laboratories is the nation’s third largest clinical laboratory; GeneDx is a rapidly growing genetic testing business; the 4Kscore® prostate cancer test is used to confirm an elevated PSA to help decide about next steps such as prostate biopsy; Claros® 1 is a point-of-care diagnostics platform with a total PSA test approved by the FDA and testosterone as the most advanced test in development. In our pharmaceutical pipeline, RAYALDEE is our first pharmaceutical product to be marketed. OPK88003, a once-weekly oxyntomodulin for type 2 diabetes and obesity recently reported positive data from a Phase 2 clinical trial. It’s among a new class of GLP-1/glucagon receptor dual agonists. OPK88004, a SARM (selective androgen receptor modulator) is currently being studied for various potential indications. The Company’s most advanced product utilizing its CTP technology, a once-weekly human growth hormone for injection, is in Phase 3 trials, and is partnered with Pfizer. OPKO also has research, development, production and distribution facilities abroad. More information is available at www.opko.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements about expectations for BioReference and GeneDx, as well as other non-historical statements about our expectations, beliefs or intentions. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the OPKO Health, Inc. Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission. Forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.